Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection
KA Ruiz-Ceja, YI Chirino - Biomedicine & Pharmacotherapy, 2017 - Elsevier
Background Lung cancer is the leading worldwide cancer with almost 1.5 million deaths
every year. Some drugs for lung cancer treatment have been available on the market for …
every year. Some drugs for lung cancer treatment have been available on the market for …
Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications
N Shaban, D Kamashev, A Emelianova, A Buzdin - Cells, 2023 - mdpi.com
Members of the EGFR family of tyrosine kinase receptors are major regulators of cellular
proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is …
proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is …
FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
C Sun, W Gao, J Liu, H Cheng, J Hao - Respiratory research, 2020 - Springer
Background This study investigated the role of fibrinogen-like protein 1 (FGL1) in regulating
gefitinib resistance of PC9/GR non-small cell lung cancer (NSCLC). Methods The effect of …
gefitinib resistance of PC9/GR non-small cell lung cancer (NSCLC). Methods The effect of …
[HTML][HTML] The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC …
M Friese-Hamim, F Bladt, G Locatelli… - American journal of …, 2017 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) sensitive to first-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) often acquires resistance through …
receptor (EGFR) tyrosine kinase inhibitors (TKIs) often acquires resistance through …
[HTML][HTML] SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p
K Wu, J Li, Y Qi, C Zhang, D Zhu, D Liu… - Biomedicine & …, 2019 - Elsevier
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been
widely used as a first-line agent in EGFR-mutant non-small cell lung cancer (NSCLC) …
widely used as a first-line agent in EGFR-mutant non-small cell lung cancer (NSCLC) …
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the …
X Wang, D Goldstein, PJ Crowe… - OncoTargets and …, 2016 - Taylor & Francis
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targeting TGFA gene expression
Aberrant expression of miR-374a has been reported in several types of human cancers,
including lung cancer. However, the functional significance and molecular mechanisms …
including lung cancer. However, the functional significance and molecular mechanisms …
Overcoming resistance to targeted therapies in cancer
KL Redmond, A Papafili, M Lawler… - Seminars in …, 2015 - Elsevier
The recent discovery of oncogenic drivers and subsequent development of novel targeted
strategies has significantly added to the therapeutic armamentarium of anti-cancer …
strategies has significantly added to the therapeutic armamentarium of anti-cancer …
Immunohistochemical analysis and comparison of napsin A, TTF1, SPA and CK7 expression in primary lung adenocarcinoma
L Jin, Y Liu, X Wang, X Qi - Biotechnic & Histochemistry, 2018 - Taylor & Francis
We investigated the expression of napsin A, TTF1, SPA and CK7 in primary lung
adenocarcinoma (ADC) and compared antibody specificity and sensitivity. We used …
adenocarcinoma (ADC) and compared antibody specificity and sensitivity. We used …
Reciprocal negative regulation between EGFR and DEPTOR plays an important role in the progression of lung adenocarcinoma
X Zhou, J Guo, Y Ji, G Pan, T Liu, H Zhu… - Molecular Cancer …, 2016 - AACR
The epidermal growth factor receptor (EGFR) activates downstream mTOR phosphorylation
to promote the progression of many different tumor types, thus making it a prime therapeutic …
to promote the progression of many different tumor types, thus making it a prime therapeutic …